Publication Topic

Proctor D, Haws L, Thompson C, Harris M. 2011. Use of mode of action and pharmacokinetics to inform the cancer risk assessment of ingested Cr(VI): A case study. Presented at the Society of Toxicology 50th Annual Meeting, Washington, DC, March 2011.

Covington T, Robinson P, Gearhart J. Exploring issues in simulating dermal exposure using a physiologically-based pharmacokinetic-pharmacodynamic (PBPK-PD) model for VX. Poster presented at the Chemical and Biological Defense Science and Technology Conference, Orlando, FL, November 2010.

Covington T, Jakubowski E, McGuire J, Byers C, Evans R, Hulet S, Whalley C, Lumley L, Clarkson E, Gearhart J. A multi-species and -route, ion- and isomer-specific physiologically-based pharmacokinetic-pharmacodynamic model for VX. Poster presented at the Bioscience Review Conference, Baltimore, MD, May 2010.

Yu KO, Ruark CD, Hack CE, Sterner TR, Covington TR, Gearhart JM. A physiologically based pharmacokinetic model for pralidoxime in the guinea pig and human. Poster presented at the Society of Toxicology Annual Meeting, Salt Lake City, UT, March 2010.

Yu K, Covington T, Ruark C, Sterner T, Hack E, Gearhart J. A physiologically based pharmacokinetic model for pralidoxime in the guinea pig and in human. Presentation at the Chemical and Biological Defense Science and Technology Conference, Dallas, TX, November 2009.

Covington TR, Jakubowski EM, McGuire JM, Byers CE, Evans RA, Hulet SW, et al. A multi-species and -route ion- and isomer-specific physiologically-based pharmacokinetic-pharmacodynamic model for VX. Presentation at the Chemical and Biological Defense Science and Technology Conference, Dallas, TX, November 2009.

Thompson CM, Johns DO, Sonawane S, Barton HA, Hattis D, Tardif R, Krishnan K. 2009. Database for physiologically based pharmacokinetic (PBPK) modeling: Physiological parameters for healthy and health-impaired elderly. J Toxicol Environ Health B 12(1):1–24; doi: 10.1080/10937400802545060.

Covington TR, Gearhart JM, Jakubowski EM, McGuire JM, Evans RA, Hulet SW. Physiologically-based pharmacokinetic/pharmacodynamic (PBPK/PD) modeling of VX exposure through various routes to multiple species. Poster presented at the Chemical and Biological Defense Physical Science and Technology Conference, New Orleans, LA, November 2008.

Thompson CM, Sonawane B, Barton HA, DeWoskin RS, Schlosser P, Lipscomb JC, Chiu W, Krishnan K. 2008. Approaches for applications of physiologically based pharmacokinetic models in risk assessment. J Toxicol Environ Health B 11(7):519–547; doi: 10.1080/10937400701724337.

Teeguarden JG, Gearhart J, Clewell HJ III, Covington TR, Nong A, Andersen ME. 2007. Pharmacokinetic modeling of manganese. III. Physiological approaches accounting for background and tracer kinetics. J Toxicol Environ Health A 70(18):1515–1526; doi: 10.1080/15287390701384635.

Teeguarden JG, Dorman DC, Nong A, Covington TR, Clewell HJ III, Andersen ME. 2007. Pharmacokinetic modeling of manganese. II. Hepatic processing after ingestion and inhalation. J Toxicol Environ Health A 70(18):1505–1514; doi: 10.1080/15287390701384619.

Teeguarden JG, Dorman DC, Covington TR, Clewell HJ III, Andersen ME. 2007. Pharmacokinetic modeling of manganese. I. Dose dependencies of uptake and elimination. J Toxicol Environ Health A 70(18):1493–1504; doi: 10.1080/15287390701384601.

Emond C, Raymer J, Garner E, Diliberto J, Staskal D, Birnbaum LS. A physiologically-based pharmacokinetic model for developmental exposure to PBDE-47 in rodents. Society of Toxicology 46th Annual Meeting, Charlotte, NC, March 2007.

Hack CE, Covington TR, Lawrence G, Shipp AM, Gentry R, Yager J, Clewell, HJ, III. 2007. A pharmacokinetic model of the intracellular dosimetry of inhaled nickel. J Toxicol Environ Health A 70(5):445–464; doi: 10.1080/15287390600870726.

Rose WC, Marathe PH, Jang G, Monticello TM, Balasubramanian BN, Long B, Fairchild C, Wall ME, Wani MC. 2006. Novel fluoro-substituted campthothecins: In vivo antitumor activity, reduced gastrointestinal toxicity and pharmacokinetic characterization. Cancer Chemother Pharmacol 58(1):73-85; doi: 10.1007/s00280-005-0128-y.

Teeguarden JG, Waechter JM Jr, Clewell HJ 3rd, Covington TR, Barton HA. 2005. Evaluation of oral and intravenous route pharmacokinetics, plasma protein binding and uterine tissue dose metrics of bisphenol A: A physiologically based pharmacokinetic approach. Toxicol Sci 85(2):429–446; doi: 10.1093/toxsci/kfi135.

Gentry PR, Haber LT, McDonald TB, Zhao Q, Covington T, Nance P, Clewell HJ III, Lipscomb JC, Barton HA. 2005. Data for physiologically based pharmacokinetic modeling in neonatal animals: Physiological parameters in mice and Sprague-Dawley rats. J Children’s Health 2(3–4):363–411; doi: 10.3109/15417060490970430.

Teeguarden JG, Waechter JM, Clewell HJ, Covington TR, Barton HA. Evaluation of oral and intravenous route pharmacokinetics, plasma protein binding and uterine tissue dose metrics of bisphenol A: A physiologically based pharmacokinetic approach. Poster presented at Society of Toxicology 44th Annual Meeting, New Orleans, LA, March 2005.

Kester JE, Gentry P, Covington TR, Clewell HJ. Issues in the use of PBPK modeling in the development of cancer slope factors for perchloroethylene. Poster presented at the Society of Toxicology 44th Annual Meeting, New Orleans, LA, March 2005.

Gentry PR, Covington TR, Mann S, Shipp AM, Yager JW, Clewell HJ III. 2004. Physiologically based pharmacokinetic modeling of arsenic in the mouse. J Toxicol Environ Health A 67(1):43–71; doi: 10.1080/15287390490253660.